![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
Head and neck cancer
December 20, 2022
This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
January 26, 2022
This phase II/III study is exploring new treatment approaches for patients with recurrent and metastatic head and neck squamous cell carcinoma
January 26, 2022
A new post-surgery approach for treating HPV-related throat cancer uses less radiation safely and spares the majority of patients from chemotherapy
August 17, 2021
This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy
February 25, 2021
This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
July 29, 2020
Learn more about a less intense treatment that preserves throat function and spares unnecessary toxicities
February 28, 2020
January meeting with NCI leaders and the Cooperative Group Chairs; Congress increases NCI and overall NIH budget for FY 2020; EA opens two new trials, one for pancreatic cyst monitoring (EA2185) and the other to evaluate nivolumab in head and neck cancer (EA3161); plans are underway for the next Comis Symposium
February 28, 2020
This trial is evaluating maintenance nivolumab versus observation following intensity-modulated radiation therapy and cisplatin